Stryker Corporation (NYSE:SYK) – Equities research analysts at Jefferies Group issued their Q1 2018 EPS estimates for shares of Stryker Corporation in a research note issued to investors on Thursday. Jefferies Group analyst R. Denhoy forecasts that the medical technology company will earn $1.61 per share for the quarter. Jefferies Group also issued estimates for Stryker Corporation’s Q2 2018 earnings at $1.68 EPS, Q3 2018 earnings at $1.67 EPS, Q4 2018 earnings at $2.14 EPS, FY2018 earnings at $7.09 EPS and FY2020 earnings at $8.47 EPS.

A number of other equities analysts also recently weighed in on the stock. Cowen and Company set a $166.00 target price on shares of Stryker Corporation and gave the stock a “buy” rating in a research note on Sunday. Barclays PLC boosted their target price on shares of Stryker Corporation from $137.00 to $148.00 and gave the stock an “underweight” rating in a research note on Friday. Canaccord Genuity boosted their target price on shares of Stryker Corporation from $155.00 to $162.00 and gave the stock a “buy” rating in a research note on Friday. Stifel Nicolaus boosted their target price on shares of Stryker Corporation from $158.00 to $168.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Wells Fargo & Company boosted their price target on shares of Stryker Corporation from $160.00 to $166.00 in a research note on Friday. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and twelve have given a buy rating to the stock. Stryker Corporation has an average rating of “Hold” and an average price target of $151.14.

WARNING: “Jefferies Group Weighs in on Stryker Corporation’s Q1 2018 Earnings (SYK)” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/10/30/jefferies-group-weighs-in-on-stryker-corporations-q1-2018-earnings-syk.html.

Shares of Stryker Corporation (NYSE:SYK) opened at 159.74 on Monday. Stryker Corporation has a 52 week low of $106.48 and a 52 week high of $160.62. The firm has a market cap of $59.75 billion, a price-to-earnings ratio of 35.66 and a beta of 0.81. The firm has a 50 day moving average of $145.58 and a 200 day moving average of $141.82.

Stryker Corporation (NYSE:SYK) last announced its quarterly earnings results on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.50 by $0.02. Stryker Corporation had a net margin of 14.67% and a return on equity of 24.11%. The company had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.97 billion. During the same quarter last year, the business earned $1.39 earnings per share. Stryker Corporation’s revenue was up 6.1% compared to the same quarter last year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, October 31st. Stockholders of record on Friday, September 29th will be issued a $0.425 dividend. This represents a $1.70 annualized dividend and a dividend yield of 1.06%. The ex-dividend date is Thursday, September 28th. Stryker Corporation’s dividend payout ratio (DPR) is presently 36.32%.

In other news, insider Graham A. Mclean sold 1,124 shares of the company’s stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $146.26, for a total value of $164,396.24. Following the completion of the transaction, the insider now owns 8,983 shares in the company, valued at $1,313,853.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Lonny J. Carpenter sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $146.36, for a total transaction of $731,800.00. Following the completion of the transaction, the insider now owns 88,207 shares of the company’s stock, valued at approximately $12,909,976.52. The disclosure for this sale can be found here. 7.40% of the stock is owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in SYK. BlackRock Inc. boosted its holdings in shares of Stryker Corporation by 2,526.4% in the first quarter. BlackRock Inc. now owns 21,976,771 shares of the medical technology company’s stock valued at $2,893,242,000 after buying an additional 21,140,000 shares during the period. Koch Industries Inc. boosted its holdings in shares of Stryker Corporation by 34,120.3% in the second quarter. Koch Industries Inc. now owns 1,260,675 shares of the medical technology company’s stock valued at $1,252,000 after buying an additional 1,256,991 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Stryker Corporation by 5.2% in the first quarter. Vanguard Group Inc. now owns 23,421,053 shares of the medical technology company’s stock valued at $3,083,382,000 after buying an additional 1,161,688 shares during the period. Janus Henderson Group PLC boosted its holdings in shares of Stryker Corporation by 2,237.8% in the second quarter. Janus Henderson Group PLC now owns 1,019,254 shares of the medical technology company’s stock valued at $141,452,000 after buying an additional 975,656 shares during the period. Finally, PNC Financial Services Group Inc. boosted its holdings in shares of Stryker Corporation by 41.9% in the first quarter. PNC Financial Services Group Inc. now owns 1,403,420 shares of the medical technology company’s stock valued at $184,759,000 after buying an additional 414,715 shares during the period. Institutional investors own 74.00% of the company’s stock.

About Stryker Corporation

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Earnings History and Estimates for Stryker Corporation (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.